Skip to main content

Table 6 Association between PET imaging parameters and overall survival, analysed as continuous variable and dichotomized at the median for the cohort

From: 18F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma

 

Ipilimumab (n = 70)

PET parameter

Level

n

HR

HR 95% CI

P-value

Tumoral SUVmax

  

0.983

[0.95,1.01]

0.24

MTV

  

1.000

[1.00, 1.001]

0.03

SLR

  

18.71

[1.34, 261.25]

0.02

Tumoral SUVmax

< 16.07

35

1

–

 

> 16.07

35

0.83

[0.42, 1.63]

0.59

MTV (mL)

< 41.38

35

1

–

 

> 41.38

35

1.09

[0.52, 2.29]

0.83

SLR

< 1.1

59

1

–

 

> 1.1

10

5.83

[2.31–14.74]

0.0002

 

Anti-PD1 (n = 40)

PET parameter

Level

n

HR

HR 95% CI

P-value

Tumoral SUVmax

  

0.967

[0.93, 1.007]

0.10

MTV

  

1.000

[0.9995, 1.001]

0.49

SLR

  

2.419

[0.08, 76.00]

0.62

Tumoral SUVmax

< 19.33

20

1

–

 

> 19.33

20

0.57

[0.21, 1.53]

0.27

MTV (mL)

< 137

20

1

–

 

> 137

20

1.67

[0.64, 4.34]

0.29

SLR

< 1.1

35

1

–

 

> 1.1

5

0.92

[0.26, 3.29]

0.89

 

First line immunotherapy (n = 90)

PET parameter

Level

n

HR

HR 95% CI

P-value

Tumoral SUVmax

  

0.986

[0.964, 1.01]

0.21

MTV

  

1.09

[1.02, 1.15]

0.02

SLR

  

17.3

[1.90, 157]

0.02

Tumoral SUVmax

≤18

49

1

–

0.05

> 18

41

0.57

[0.32, 1.01]

 

MTV (mL)

≤76

51

1

–

0.61

> 76

39

1.18

[0.63, 2.23]

 

SLR

≤1.1

79

1

–

0.003

> 1.1

10

3.92

[1.76, 8.72]

 
  1. PET Positron emission tomography; SUVmax Maximum Standardised Uptake Value; MTV Metabolic Tumour Volume; SLR Spleen to Liver Ratio